Physician profile
Dean Spencer
NPI 1043213465
$11,850.40
in general payments reported to CMS, 2019-2025
45 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,311 · 2020: $1,139 · 2021: $1,847 · 2022: $1,697 · 2023: $1,779 · 2024: $1,506 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,751 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,751.00 |
| Education | $104.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,657.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,011.75 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $931.83 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $779.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $746.63 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $716.86 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $607.82 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $550.60 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $523.42 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.13 | 2019-2022 | |
| Abbvie INC. | $432.49 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $411.64 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $407.29 | 2019-2024 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $403.38 | 2019 | |
| Abbott Laboratories | $359.00 | 2023-2024 | Epic, Sjm Masters Series |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.